Seed Therapeutics logo

 

LEADERSHIP TEAM

leadership team
Lan Huang, Ph.D.

Lan Huang, Ph.D.

Chief Executive Officer

Rich Daly

Richard Daly

Chief Operating Officer

Edward Liu
Edward Dongheng Liu

Chief Financial Officer

Close

Richard Daly

Chief Operating Officer
Mr. Daly joins the company with more than 25 years of experience leading business and commercial operations for major pharmaceutical and biotech companies, including Executive Vice President at Takeda Pharmaceuticals U.S.A., Inc. and as President of AstraZeneca’s U.S. Diabetes subsidiary. Most recently, Mr. Daly served as CEO, President, and Chairman of Neuralstem, Inc. Mr. Daly currently serves on the boards of Catalyst Pharmaceuticals and Opiant Pharmaceuticals.

Mr. Daly was instrumental in building Takeda North America from 14 people to more than 3,000 employees and $5 billion in sales in less than seven years. During his 13-year tenure, he served as Executive Vice President for the U.S., where he was responsible for business development for the Americas and expanding the company’s commercial footprint across North and South America and into new therapeutic areas, including oncology. As President of AstraZeneca’s U.S. Diabetes subsidiary, Mr. Daly led commercial initiatives that transformed the Bristol-Myers Squibb and AstraZeneca Diabetes Alliance into the fastest-growing diabetes franchise in the U.S. in less than 12 months.

Mr. Daly earned an M.B.A. from Northwestern University’s Kellogg School of Management and holds a B.S. in microbiology from the University of Notre Dame.

Close

Lan Huang, Ph.D.

Chief Executive Officer
Dr. Huang brings over 15 years of entrepreneurial experience in the Chinese and U.S. biotechnology industries. In 2010, Dr. Huang founded Wanchun Biotech, the former holding company of BeyondSpring’s U.S. subsidiary. In 2007, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd., where she served as CEO in 2010 and continues to hold a directorship. The rights related to the development and marketing of the peptide drug in China, which drug Dr. Huang designed while at Wuxi MTLH Biotechnology Co. Ltd., were sold to Shanghai Pharmaceutical Co., Ltd. in 2010. Additionally, in 2008, Dr. Huang co-founded Paramax International Inc., a CRO that conducts clinical trials for global biopharmaceutical and medical device companies. Paramax International Inc. was acquired by ReSearch Pharmaceutical Services, Inc. in 2009. Dr. Huang was trained at Memorial Sloan Kettering Cancer Center from 1998 to 2002, where her research in cancer signaling pathways involving p53 degradation was published in Science. Her translational research in cancer signaling pathways involving RAS was published in two Nature papers. She has invented and holds patents for a number of biotech products for oncology and dermatology indications.

Dr. Huang received her B.A., Magna Cum Laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee from 2012 to 2015. She received her Ph.D. in chemistry from the University of California at Berkeley, where she won the international-level Women’s Opportunity Award given by Soroptimist International. She also studied at Fudan University in Shanghai, China.

Close

Edward Dongheng Liu

Chief Financial Officer
Mr. Liu joins Seed Therapeutics with more than a decade of investment banking and investment experience in the Asia-Pacific region and currently is Chief Financial Officer, China for BeyondSpring, Inc.

Prior to joining BeyondSpring, Mr. Liu was a Partner and Executive Director at Epiphron Capital, a cross-border, healthcare-focused investment fund that was an early investor in BeyondSpring. Prior to that, he held various leadership positions in the investment banking industry based in Hong Kong focusing on clients in the Asia-Pacific region. He was Senior Vice President and Vice President at Investment Banking and Capital Markets at Jefferies. Prior to Jefferies, he served as Vice President at Investment Banking Division at J.P. Morgan. As an investment banker, Mr. Liu has led financing and M&A transactions for clients across sectors with a total transaction value exceeding US$30 billion.

Mr. Liu received his Bachelor’s degree in Economics and Mathematics from Yale University. He also completed biomedical engineering coursework at Tsinghua University.

James Tonra, Ph.D.
James Tonra, Ph.D.

Chief Scientific Officer

Paul Friel

Paul Friel

Vice President, Business Development

Close

Paul Friel

Vice President, Business Development
Mr. Friel joins Seed Therapeutics as Vice President of Business Development. With almost 30 years of experience in the pharmaceutical and biotech industry, he has held positions as General Manager and President at Takeda Canada and Vice President of Sales for Vyaire. Currently, Mr. Friel serves as Chief Commercial Officer for BeyondSpring, Inc.

Mr. Friel was instrumental in building TAP Pharmaceuticals and Takeda North America to more than 5,000 employees and $10 billion in sales in less than 10 years. During his 24-year tenure at TAP and Takeda, he served in multiple commercial roles and was responsible for business development, integration, geographic expansion, and Head of Commercial for Latin America for Takeda. Mr. Friel later served as General Manager and President for Takeda Canada and lead Takeda expansions into Mexico, Brazil, and Canada. In the last 4 years of Mr. Friel’s tenure at Takeda, he was integral for launching eight products, including the second fastest biologic launch in the U.S.

Mr. Friel earned an M.B.A. from the University of Kansas and holds a B.S. in business administration from the Kansas State University.

Close

James Tonra, Ph.D.

Chief Scientific Officer
Dr. Tonra has worked for 24 years in biotechnology, leading and utilizing in-house, contracted and sponsored research efforts to generate definitive data packages that enable the advancement of research projects to investigational new drug (IND) filing and guide clinical development at Regeneron Pharmaceuticals, Millennium Pharmaceuticals, ImClone Systems/Eli Lilly, Kadmon Holdings and BeyondSpring.

Dr. Tonra has collaborated with and lead multidisciplinary project teams to develop biologic and small-molecule drug candidates for disease indications including oncology, CNS disorders, inflammation and diabetes. He has authored over 45 peer-reviewed publications and is an inventor on numerous use-patents. In the nearly 10 years Dr. Tonra spent at ImClone/Eli Lilly, his efforts were critical in the validation and IND filing for 10 preclinical assets, including Cyramza®, Portrazza®, and Lartruvo®. Moreover, Dr. Tonra’s work at ImClone/Eli Lilly demonstrated synergy between the combination of agents such as Cyramza® and Tarceva®, recently shown to have meaningful clinical benefit in a subtype of non-small cell lung cancer patients. At BeyondSpring, Dr. Tonra is the Chief Scientific Officer and was instrumental in advancing the company’s immune-oncology strategy and ubiquitination platform. He is part of the team that discovered plinabulin’s differentiated mechanism of action and was instrumental in expanding plinabulin’s clinical indications through outsourced nonclinical research and collaborations with leading academic experts.

Dr. Tonra received his Ph.D. in Physiology and Biophysics from SUNY at Stony Brook and a B.S. in Physics, Summa Cum Laude, from SUNY at Stony Brook.

LEADERSHIP TEAM

leadership team
Lan Huang, Ph.D.
Lan Huang, Ph.D.

Chief Executive Officer

Rich Daly

Richard Daly

Chief Operating Officer

Close

Lan Huang, Ph.D.

Chief Executive Officer
Dr. Huang brings over 15 years of entrepreneurial experience in the Chinese and U.S. biotechnology industries. In 2010, Dr. Huang founded Wanchun Biotech, the former holding company of BeyondSpring’s U.S. subsidiary. In 2007, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd., where she served as CEO in 2010 and continues to hold a directorship. The rights related to the development and marketing of the peptide drug in China, which drug Dr. Huang designed while at Wuxi MTLH Biotechnology Co. Ltd., were sold to Shanghai Pharmaceutical Co., Ltd. in 2010. Additionally, in 2008, Dr. Huang co-founded Paramax International Inc., a CRO that conducts clinical trials for global biopharmaceutical and medical device companies. Paramax International Inc. was acquired by ReSearch Pharmaceutical Services, Inc. in 2009. Dr. Huang was trained at Memorial Sloan Kettering Cancer Center from 1998 to 2002, where her research in cancer signaling pathways involving p53 degradation was published in Science. Her translational research in cancer signaling pathways involving RAS was published in two Nature papers. She has invented and holds patents for a number of biotech products for oncology and dermatology indications.

Dr. Huang received her B.A., Magna Cum Laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee from 2012 to 2015. She received her Ph.D. in chemistry from the University of California at Berkeley, where she won the international-level Women’s Opportunity Award given by Soroptimist International. She also studied at Fudan University in Shanghai, China.

Close

Richard Daly

Chief Operating Officer
Mr. Daly joins the company with more than 25 years of experience leading business and commercial operations for major pharmaceutical and biotech companies, including Executive Vice President at Takeda Pharmaceuticals U.S.A., Inc. and as President of AstraZeneca’s U.S. Diabetes subsidiary. Most recently, Mr. Daly served as CEO, President, and Chairman of Neuralstem, Inc. Mr. Daly currently serves on the boards of Catalyst Pharmaceuticals and Opiant Pharmaceuticals.

Mr. Daly was instrumental in building Takeda North America from 14 people to more than 3,000 employees and $5 billion in sales in less than seven years. During his 13-year tenure, he served as Executive Vice President for the U.S., where he was responsible for business development for the Americas and expanding the company’s commercial footprint across North and South America and into new therapeutic areas, including oncology. As President of AstraZeneca’s U.S. Diabetes subsidiary, Mr. Daly led commercial initiatives that transformed the Bristol-Myers Squibb and AstraZeneca Diabetes Alliance into the fastest-growing diabetes franchise in the U.S. in less than 12 months.

Mr. Daly earned an M.B.A. from Northwestern University’s Kellogg School of Management and holds a B.S. in microbiology from the University of Notre Dame.

Edward Liu
Edward Dongheng Liu

Chief Financial Officer

James Tonra, Ph.D.
James Tonra, Ph.D.

Chief Scientific Officer

Close

James Tonra, Ph.D.

Chief Scientific Officer
Dr. Tonra has worked for 24 years in biotechnology, leading and utilizing in-house, contracted and sponsored research efforts to generate definitive data packages that enable the advancement of research projects to investigational new drug (IND) filing and guide clinical development at Regeneron Pharmaceuticals, Millennium Pharmaceuticals, ImClone Systems/Eli Lilly, Kadmon Holdings and BeyondSpring.

Dr. Tonra has collaborated with and lead multidisciplinary project teams to develop biologic and small-molecule drug candidates for disease indications including oncology, CNS disorders, inflammation and diabetes. He has authored over 45 peer-reviewed publications and is an inventor on numerous use-patents. In the nearly 10 years Dr. Tonra spent at ImClone/Eli Lilly, his efforts were critical in the validation and IND filing for 10 preclinical assets, including Cyramza®, Portrazza®, and Lartruvo®. Moreover, Dr. Tonra’s work at ImClone/Eli Lilly demonstrated synergy between the combination of agents such as Cyramza® and Tarceva®, recently shown to have meaningful clinical benefit in a subtype of non-small cell lung cancer patients. At BeyondSpring, Dr. Tonra is the Chief Scientific Officer and was instrumental in advancing the company’s immune-oncology strategy and ubiquitination platform. He is part of the team that discovered plinabulin’s differentiated mechanism of action and was instrumental in expanding plinabulin’s clinical indications through outsourced nonclinical research and collaborations with leading academic experts.

Dr. Tonra received his Ph.D. in Physiology and Biophysics from SUNY at Stony Brook and a B.S. in Physics, Summa Cum Laude, from SUNY at Stony Brook.

Close

Edward Dongheng Liu

Chief Financial Officer
Mr. Liu joins Seed Therapeutics with more than a decade of investment banking and investment experience in the Asia-Pacific region and currently is Chief Financial Officer, China for BeyondSpring, Inc.

Prior to joining BeyondSpring, Mr. Liu was a Partner and Executive Director at Epiphron Capital, a cross-border, healthcare-focused investment fund that was an early investor in BeyondSpring. Prior to that, he held various leadership positions in the investment banking industry based in Hong Kong focusing on clients in the Asia-Pacific region. He was Senior Vice President and Vice President at Investment Banking and Capital Markets at Jefferies. Prior to Jefferies, he served as Vice President at Investment Banking Division at J.P. Morgan. As an investment banker, Mr. Liu has led financing and M&A transactions for clients across sectors with a total transaction value exceeding US$30 billion.

Mr. Liu received his Bachelor’s degree in Economics and Mathematics from Yale University. He also completed biomedical engineering coursework at Tsinghua University.

Paul Friel
Paul Friel

Vice President, Business Development

Close

Paul Friel

Vice President, Business Development
Mr. Friel joins Seed Therapeutics as Vice President of Business Development. With almost 30 years of experience in the pharmaceutical and biotech industry, he has held positions as General Manager and President at Takeda Canada and Vice President of Sales for Vyaire. Currently, Mr. Friel serves as Chief Commercial Officer for BeyondSpring, Inc.

Mr. Friel was instrumental in building TAP Pharmaceuticals and Takeda North America to more than 5,000 employees and $10 billion in sales in less than 10 years. During his 24-year tenure at TAP and Takeda, he served in multiple commercial roles and was responsible for business development, integration, geographic expansion, and Head of Commercial for Latin America for Takeda. Mr. Friel later served as General Manager and President for Takeda Canada and lead Takeda expansions into Mexico, Brazil, and Canada. In the last 4 years of Mr. Friel’s tenure at Takeda, he was integral for launching eight products, including the second fastest biologic launch in the U.S.

Mr. Friel earned an M.B.A. from the University of Kansas and holds a B.S. in business administration from the Kansas State University.

LEADERSHIP TEAM

leadership team
Lan Huang, Ph.D.
Lan Huang, Ph.D.

Chief Executive Officer

Close

Lan Huang, Ph.D.

Chief Executive Officer
Dr. Huang brings over 15 years of entrepreneurial experience in the Chinese and U.S. biotechnology industries. In 2010, Dr. Huang founded Wanchun Biotech, the former holding company of BeyondSpring’s U.S. subsidiary. In 2007, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd., where she served as CEO in 2010 and continues to hold a directorship. The rights related to the development and marketing of the peptide drug in China, which drug Dr. Huang designed while at Wuxi MTLH Biotechnology Co. Ltd., were sold to Shanghai Pharmaceutical Co., Ltd. in 2010. Additionally, in 2008, Dr. Huang co-founded Paramax International Inc., a CRO that conducts clinical trials for global biopharmaceutical and medical device companies. Paramax International Inc. was acquired by ReSearch Pharmaceutical Services, Inc. in 2009. Dr. Huang was trained at Memorial Sloan Kettering Cancer Center from 1998 to 2002, where her research in cancer signaling pathways involving p53 degradation was published in Science. Her translational research in cancer signaling pathways involving RAS was published in two Nature papers. She has invented and holds patents for a number of biotech products for oncology and dermatology indications.

Dr. Huang received her B.A., Magna Cum Laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee from 2012 to 2015. She received her Ph.D. in chemistry from the University of California at Berkeley, where she won the international-level Women’s Opportunity Award given by Soroptimist International. She also studied at Fudan University in Shanghai, China.

Rich Daly

Richard Daly

Chief Operating Officer

Close

Richard Daly

Chief Operating Officer
Mr. Daly joins the company with more than 25 years of experience leading business and commercial operations for major pharmaceutical and biotech companies, including Executive Vice President at Takeda Pharmaceuticals U.S.A., Inc. and as President of AstraZeneca’s U.S. Diabetes subsidiary. Most recently, Mr. Daly served as CEO, President, and Chairman of Neuralstem, Inc. Mr. Daly currently serves on the boards of Catalyst Pharmaceuticals and Opiant Pharmaceuticals.

Mr. Daly was instrumental in building Takeda North America from 14 people to more than 3,000 employees and $5 billion in sales in less than seven years. During his 13-year tenure, he served as Executive Vice President for the U.S., where he was responsible for business development for the Americas and expanding the company’s commercial footprint across North and South America and into new therapeutic areas, including oncology. As President of AstraZeneca’s U.S. Diabetes subsidiary, Mr. Daly led commercial initiatives that transformed the Bristol-Myers Squibb and AstraZeneca Diabetes Alliance into the fastest-growing diabetes franchise in the U.S. in less than 12 months.

Mr. Daly earned an M.B.A. from Northwestern University’s Kellogg School of Management and holds a B.S. in microbiology from the University of Notre Dame.

Edward Liu
Edward Dongheng Liu

Chief Financial Officer

Close

Edward Dongheng Liu

Chief Financial Officer
Mr. Liu joins Seed Therapeutics with more than a decade of investment banking and investment experience in the Asia-Pacific region and currently is Chief Financial Officer, China for BeyondSpring, Inc.

Prior to joining BeyondSpring, Mr. Liu was a Partner and Executive Director at Epiphron Capital, a cross-border, healthcare-focused investment fund that was an early investor in BeyondSpring. Prior to that, he held various leadership positions in the investment banking industry based in Hong Kong focusing on clients in the Asia-Pacific region. He was Senior Vice President and Vice President at Investment Banking and Capital Markets at Jefferies. Prior to Jefferies, he served as Vice President at Investment Banking Division at J.P. Morgan. As an investment banker, Mr. Liu has led financing and M&A transactions for clients across sectors with a total transaction value exceeding US$30 billion.

Mr. Liu received his Bachelor’s degree in Economics and Mathematics from Yale University. He also completed biomedical engineering coursework at Tsinghua University.

James Tonra, Ph.D.
James Tonra, Ph.D.

Chief Scientific Officer

Close

James Tonra, Ph.D.

Chief Scientific Officer
Dr. Tonra has worked for 24 years in biotechnology, leading and utilizing in-house, contracted and sponsored research efforts to generate definitive data packages that enable the advancement of research projects to investigational new drug (IND) filing and guide clinical development at Regeneron Pharmaceuticals, Millennium Pharmaceuticals, ImClone Systems/Eli Lilly, Kadmon Holdings and BeyondSpring.

Dr. Tonra has collaborated with and lead multidisciplinary project teams to develop biologic and small-molecule drug candidates for disease indications including oncology, CNS disorders, inflammation and diabetes. He has authored over 45 peer-reviewed publications and is an inventor on numerous use-patents. In the nearly 10 years Dr. Tonra spent at ImClone/Eli Lilly, his efforts were critical in the validation and IND filing for 10 preclinical assets, including Cyramza®, Portrazza®, and Lartruvo®. Moreover, Dr. Tonra’s work at ImClone/Eli Lilly demonstrated synergy between the combination of agents such as Cyramza® and Tarceva®, recently shown to have meaningful clinical benefit in a subtype of non-small cell lung cancer patients. At BeyondSpring, Dr. Tonra is the Chief Scientific Officer and was instrumental in advancing the company’s immune-oncology strategy and ubiquitination platform. He is part of the team that discovered plinabulin’s differentiated mechanism of action and was instrumental in expanding plinabulin’s clinical indications through outsourced nonclinical research and collaborations with leading academic experts.

Dr. Tonra received his Ph.D. in Physiology and Biophysics from SUNY at Stony Brook and a B.S. in Physics, Summa Cum Laude, from SUNY at Stony Brook.

Paul Friel
Paul Friel

Vice President, Business Development

Close

Paul Friel

Vice President, Business Development
Mr. Friel joins Seed Therapeutics as Vice President of Business Development. With almost 30 years of experience in the pharmaceutical and biotech industry, he has held positions as General Manager and President at Takeda Canada and Vice President of Sales for Vyaire. Currently, Mr. Friel serves as Chief Commercial Officer for BeyondSpring, Inc.

Mr. Friel was instrumental in building TAP Pharmaceuticals and Takeda North America to more than 5,000 employees and $10 billion in sales in less than 10 years. During his 24-year tenure at TAP and Takeda, he served in multiple commercial roles and was responsible for business development, integration, geographic expansion, and Head of Commercial for Latin America for Takeda. Mr. Friel later served as General Manager and President for Takeda Canada and lead Takeda expansions into Mexico, Brazil, and Canada. In the last 4 years of Mr. Friel’s tenure at Takeda, he was integral for launching eight products, including the second fastest biologic launch in the U.S.

Mr. Friel earned an M.B.A. from the University of Kansas and holds a B.S. in business administration from the Kansas State University.

SCIENTIFIC ADVISORS

scientific advisors
Lan Huang, Ph.D.

Lan Huang, Ph.D.

Founder, Seed Therapeutics, Inc. and BeyondSpring, Inc.
Ubiquitin ligase expert and biotech entrepreneur

Ning Zheng, Ph.D.

Ning Zheng, Ph.D.

Pioneer in molecular glue discovery and scientific structural rationale

Michele Pagano, M.D.

Michele Pagano, M.D.

World leader in the discovery and application of ubiquitin ligase biology and cancer biology

Avram Hershko, M.D., Ph.D.

Avram Hershko, M.D., Ph.D.

Pioneer in the ubiquitin-proteasome system Nobel Prize Recipient

Close

Avram Hershko, M.D., Ph.D.

A winner of the Nobel Prize in Chemistry in 2004 and co-winner of the Lasker Award in 2000, Dr. Hershko was the first researcher to describe the ubiquitin system responsible for the regulated degradation of proteins within the cell. This discovery represented a breakthrough in research on cancer, degenerative diseases in the brain, and many other disorders. He is currently a Distinguished Professor in the Department of Biochemistry at Technion – Israel Institute of Technology in Haifa, Israel and has been an adjunct professor of Pathology at the NYU School of Medicine since 2002. Additional information on Dr. Hershko can be found at https://en.wikipedia.org/wiki/Avram_Hershko.

Close

Michele Pagano, M.D.

Dr. Pagano is the chair of the Department of Biochemistry and Molecular Pharmacology and the May Ellen and Gerald Jay Ritter professor of Oncology at the New York University School of Medicine. Since 2008, he is also an investigator at the Howard Hughes Medical Institute. Dr. Pagano received his doctorate in Medicine and a specialty diploma in Molecular Endocrinology in 1990 from the University of Naples Federico II University in his native Napoli, Italy. He was subsequently a post-doctoral fellow at EMBL, Heidelberg, Germany from 1990 to 1992, and at Mitotix Inc., a biotech company that he cofounded and that pioneered the concept of CDK inhibitors as anti-cancer agents from 1992 to 1996. He joined the NYU School of Medicine in September 1996 and was tenured in 2003. Dr. Pagano has received many prestigious grants, including a Merit Award from the National Cancer Institute (2006-2017) and a NIGMS MIRA Award in recognition of his outstanding achievements in cell and cancer biology. Dr. Pagano has published more than 200 leading papers, has been issued 7 patents, and has been invited to present more than 180 seminars at conferences, universities, and research institutions in the U.S. and abroad. Dr. Pagano’s research focuses on the ubiquitylating enzymes that control cell proliferation and how deregulation of these machineries contribute to malignant transformation. His long-term goal is to help develop new anticancer therapies. In particular, his laboratory is working towards the identification of small molecule glues able to promote the proteolysis of untargetable oncoproteins. Additional information on The Pagano Laboratory can be found at http://paganolab.org.

Close

Ning Zheng, Ph.D.

Dr. Zheng is a Professor of Pharmacology at the University of Washington School of Medicine and a Howard Hughes Medical Institute Investigator. He received his Ph.D. from the University of Texas Southwestern Medical Center and was trained as a Postdoctoral Fellow at the Memorial Sloan-Kettering Cancer Center. Research in Dr. Zheng’s group seeks to understand the intricate interactions and coordinated functions of proteins and signaling molecules found in all kingdoms of life. Using a structural biology approach, Dr. Zheng and his team conduct studies that span several interwoven research areas, including protein ubiquitination, transcription regulation, plant hormone signaling, and ion channel functions. In the past two decades, the Zheng lab has elucidated various regulatory mechanisms governing specific substrate recognition by ubiquitin ligases. He raised the concept of “molecular glue” for the first time based on his discovery of the mechanism of action of auxin, a master plant hormone targeting a ubiquitin ligase-substrate interface. The overarching goal of his studies is to apply the biological principles they learn from basic research to the development of novel therapeutics and the balancing of the planet’s ecological systems. Additional information on The Zheng Lab at UW can be found at https://depts.washington.edu/zhenglab/.

Close

Lan Huang, Ph.D.

Dr. Huang brings over 15 years of entrepreneurial experience in the Chinese and U.S. biotechnology industries. In 2010, Dr. Huang founded Wanchun Biotech, the former holding company of BeyondSpring’s U.S. subsidiary. In 2007, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd., where she served as CEO in 2010 and continues to hold a directorship. The rights related to the development and marketing of the peptide drug in China, which drug Dr. Huang designed while at Wuxi MTLH Biotechnology Co. Ltd., were sold to Shanghai Pharmaceutical Co., Ltd. in 2010. Additionally, in 2008, Dr. Huang co-founded Paramax International Inc., a CRO that conducts clinical trials for global biopharmaceutical and medical device companies. Paramax International Inc. was acquired by ReSearch Pharmaceutical Services, Inc. in 2009. Dr. Huang was trained at Memorial Sloan Kettering Cancer Center from 1998 to 2002, where her research in cancer signaling pathways involving p53 degradation was published in Science. Her translational research in cancer signaling pathways involving RAS was published in two Nature papers. She has invented and holds patents for a number of biotech products for oncology and dermatology indications.

Dr. Huang received her B.A., Magna Cum Laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee from 2012 to 2015. She received her Ph.D. in chemistry from the University of California at Berkeley, where she won the international-level Women’s Opportunity Award given by Soroptimist International. She also studied at Fudan University in Shanghai, China.

SCIENTIFIC ADVISORS

scientific advisors
Lan Huang, Ph.D.

Lan Huang, Ph.D.

Founder, Seed Therapeutics, Inc. and BeyondSpring, Inc.
Ubiquitin ligase expert and biotech entrepreneur

Ning Zheng, Ph.D.

Ning Zheng, Ph.D.

Pioneer in molecular glue discovery and scientific structural rationale

Close

Lan Huang, Ph.D.

Dr. Huang brings over 15 years of entrepreneurial experience in the Chinese and U.S. biotechnology industries. In 2010, Dr. Huang founded Wanchun Biotech, the former holding company of BeyondSpring’s U.S. subsidiary. In 2007, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd., where she served as CEO in 2010 and continues to hold a directorship. The rights related to the development and marketing of the peptide drug in China, which drug Dr. Huang designed while at Wuxi MTLH Biotechnology Co. Ltd., were sold to Shanghai Pharmaceutical Co., Ltd. in 2010. Additionally, in 2008, Dr. Huang co-founded Paramax International Inc., a CRO that conducts clinical trials for global biopharmaceutical and medical device companies. Paramax International Inc. was acquired by ReSearch Pharmaceutical Services, Inc. in 2009. Dr. Huang was trained at Memorial Sloan Kettering Cancer Center from 1998 to 2002, where her research in cancer signaling pathways involving p53 degradation was published in Science. Her translational research in cancer signaling pathways involving RAS was published in two Nature papers. She has invented and holds patents for a number of biotech products for oncology and dermatology indications.

Dr. Huang received her B.A., Magna Cum Laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee from 2012 to 2015. She received her Ph.D. in chemistry from the University of California at Berkeley, where she won the international-level Women’s Opportunity Award given by Soroptimist International. She also studied at Fudan University in Shanghai, China.

Close

Ning Zheng, Ph.D.

Dr. Zheng is a Professor of Pharmacology at the University of Washington School of Medicine and a Howard Hughes Medical Institute Investigator. He received his Ph.D. from the University of Texas Southwestern Medical Center and was trained as a Postdoctoral Fellow at the Memorial Sloan-Kettering Cancer Center. Research in Dr. Zheng’s group seeks to understand the intricate interactions and coordinated functions of proteins and signaling molecules found in all kingdoms of life. Using a structural biology approach, Dr. Zheng and his team conduct studies that span several interwoven research areas, including protein ubiquitination, transcription regulation, plant hormone signaling, and ion channel functions. In the past two decades, the Zheng lab has elucidated various regulatory mechanisms governing specific substrate recognition by ubiquitin ligases. He raised the concept of “molecular glue” for the first time based on his discovery of the mechanism of action of auxin, a master plant hormone targeting a ubiquitin ligase-substrate interface. The overarching goal of his studies is to apply the biological principles they learn from basic research to the development of novel therapeutics and the balancing of the planet’s ecological systems. Additional information on The Zheng Lab at UW can be found at https://depts.washington.edu/zhenglab/.

Michele Pagano

Michele Pagano, M.D.

World leader in the discovery and application of ubiquitin ligase biology and cancer biology

Avram Hershko, M.D., Ph.D.

Avram Hershko, M.D., Ph.D.

Pioneer in the ubiquitin-proteasome system Nobel Prize Recipient

Close

Avram Hershko, M.D., Ph.D.

A winner of the Nobel Prize in Chemistry in 2004 and co-winner of the Lasker Award in 2000, Dr. Hershko was the first researcher to describe the ubiquitin system responsible for the regulated degradation of proteins within the cell. This discovery represented a breakthrough in research on cancer, degenerative diseases in the brain, and many other disorders. He is currently a Distinguished Professor in the Department of Biochemistry at Technion – Israel Institute of Technology in Haifa, Israel and has been an adjunct professor of Pathology at the NYU School of Medicine since 2002. Additional information on Dr. Hershko can be found at https://en.wikipedia.org/wiki/Avram_Hershko.

Close

Michele Pagano, M.D.

Dr. Pagano is the chair of the Department of Biochemistry and Molecular Pharmacology and the May Ellen and Gerald Jay Ritter professor of Oncology at the New York University School of Medicine. Since 2008, he is also an investigator at the Howard Hughes Medical Institute. Dr. Pagano received his doctorate in Medicine and a specialty diploma in Molecular Endocrinology in 1990 from the University of Naples Federico II University in his native Napoli, Italy. He was subsequently a post-doctoral fellow at EMBL, Heidelberg, Germany from 1990 to 1992, and at Mitotix Inc., a biotech company that he cofounded and that pioneered the concept of CDK inhibitors as anti-cancer agents from 1992 to 1996. He joined the NYU School of Medicine in September 1996 and was tenured in 2003. Dr. Pagano has received many prestigious grants, including a Merit Award from the National Cancer Institute (2006-2017) and a NIGMS MIRA Award in recognition of his outstanding achievements in cell and cancer biology. Dr. Pagano has published more than 200 leading papers, has been issued 7 patents, and has been invited to present more than 180 seminars at conferences, universities, and research institutions in the U.S. and abroad. Dr. Pagano’s research focuses on the ubiquitylating enzymes that control cell proliferation and how deregulation of these machineries contribute to malignant transformation. His long-term goal is to help develop new anticancer therapies. In particular, his laboratory is working towards the identification of small molecule glues able to promote the proteolysis of untargetable oncoproteins. Additional information on The Pagano Laboratory can be found at http://paganolab.org.

SCIENTIFIC ADVISORS

scientific advisors
Lan Huang, Ph.D.

Lan Huang, Ph.D.

Founder, Seed Therapeutics, Inc. and BeyondSpring, Inc.
Ubiquitin ligase expert and biotech entrepreneur

Close

Lan Huang, Ph.D.

Dr. Huang brings over 15 years of entrepreneurial experience in the Chinese and U.S. biotechnology industries. In 2010, Dr. Huang founded Wanchun Biotech, the former holding company of BeyondSpring’s U.S. subsidiary. In 2007, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd., where she served as CEO in 2010 and continues to hold a directorship. The rights related to the development and marketing of the peptide drug in China, which drug Dr. Huang designed while at Wuxi MTLH Biotechnology Co. Ltd., were sold to Shanghai Pharmaceutical Co., Ltd. in 2010. Additionally, in 2008, Dr. Huang co-founded Paramax International Inc., a CRO that conducts clinical trials for global biopharmaceutical and medical device companies. Paramax International Inc. was acquired by ReSearch Pharmaceutical Services, Inc. in 2009. Dr. Huang was trained at Memorial Sloan Kettering Cancer Center from 1998 to 2002, where her research in cancer signaling pathways involving p53 degradation was published in Science. Her translational research in cancer signaling pathways involving RAS was published in two Nature papers. She has invented and holds patents for a number of biotech products for oncology and dermatology indications.

Dr. Huang received her B.A., Magna Cum Laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee from 2012 to 2015. She received her Ph.D. in chemistry from the University of California at Berkeley, where she won the international-level Women’s Opportunity Award given by Soroptimist International. She also studied at Fudan University in Shanghai, China.

Ning Zheng, Ph.D.

Ning Zheng, Ph.D.

Pioneer in molecular glue discovery and scientific structural rationale

Close

Ning Zheng, Ph.D.

Dr. Zheng is a Professor of Pharmacology at the University of Washington School of Medicine and a Howard Hughes Medical Institute Investigator. He received his Ph.D. from the University of Texas Southwestern Medical Center and was trained as a Postdoctoral Fellow at the Memorial Sloan-Kettering Cancer Center. Research in Dr. Zheng’s group seeks to understand the intricate interactions and coordinated functions of proteins and signaling molecules found in all kingdoms of life. Using a structural biology approach, Dr. Zheng and his team conduct studies that span several interwoven research areas, including protein ubiquitination, transcription regulation, plant hormone signaling, and ion channel functions. In the past two decades, the Zheng lab has elucidated various regulatory mechanisms governing specific substrate recognition by ubiquitin ligases. He raised the concept of “molecular glue” for the first time based on his discovery of the mechanism of action of auxin, a master plant hormone targeting a ubiquitin ligase-substrate interface. The overarching goal of his studies is to apply the biological principles they learn from basic research to the development of novel therapeutics and the balancing of the planet’s ecological systems. Additional information on The Zheng Lab at UW can be found at https://depts.washington.edu/zhenglab/.

Michele Pagano

Michele Pagano, M.D.

World leader in the discovery and application of ubiquitin ligase biology and cancer biology

Close

Michele Pagano, M.D.

Dr. Pagano is the chair of the Department of Biochemistry and Molecular Pharmacology and the May Ellen and Gerald Jay Ritter professor of Oncology at the New York University School of Medicine. Since 2008, he is also an investigator at the Howard Hughes Medical Institute. Dr. Pagano received his doctorate in Medicine and a specialty diploma in Molecular Endocrinology in 1990 from the University of Naples Federico II University in his native Napoli, Italy. He was subsequently a post-doctoral fellow at EMBL, Heidelberg, Germany from 1990 to 1992, and at Mitotix Inc., a biotech company that he cofounded and that pioneered the concept of CDK inhibitors as anti-cancer agents from 1992 to 1996. He joined the NYU School of Medicine in September 1996 and was tenured in 2003. Dr. Pagano has received many prestigious grants, including a Merit Award from the National Cancer Institute (2006-2017) and a NIGMS MIRA Award in recognition of his outstanding achievements in cell and cancer biology. Dr. Pagano has published more than 200 leading papers, has been issued 7 patents, and has been invited to present more than 180 seminars at conferences, universities, and research institutions in the U.S. and abroad. Dr. Pagano’s research focuses on the ubiquitylating enzymes that control cell proliferation and how deregulation of these machineries contribute to malignant transformation. His long-term goal is to help develop new anticancer therapies. In particular, his laboratory is working towards the identification of small molecule glues able to promote the proteolysis of untargetable oncoproteins. Additional information on The Pagano Laboratory can be found at http://paganolab.org.

Avram Hershko, M.D., Ph.D.

Avram Hershko, M.D., Ph.D.

Pioneer in the ubiquitin-proteasome system Nobel Prize Recipient

Close

Avram Hershko, M.D., Ph.D.

A winner of the Nobel Prize in Chemistry in 2004 and co-winner of the Lasker Award in 2000, Dr. Hershko was the first researcher to describe the ubiquitin system responsible for the regulated degradation of proteins within the cell. This discovery represented a breakthrough in research on cancer, degenerative diseases in the brain, and many other disorders. He is currently a Distinguished Professor in the Department of Biochemistry at Technion – Israel Institute of Technology in Haifa, Israel and has been an adjunct professor of Pathology at the NYU School of Medicine since 2002. Additional information on Dr. Hershko can be found at https://en.wikipedia.org/wiki/Avram_Hershko.

BOARD OF DIRECTORS

Board of Directors
Lan Huang, Ph.D.

Lan Huang, Ph.D.

Co-founder, Chairman & Chief Executive Officer

Rich Daly
Richard Daly

Director

Edward Liu
Edward Dongheng Liu

Director

Close

Richard Daly

Mr. Daly has served on the Board of Directors of Seed Therapeutics, Inc. since October 2020.

Mr. Daly joins the company with more than 25 years of experience leading business and commercial operations for major pharmaceutical and biotech companies, including Executive Vice President at Takeda Pharmaceuticals U.S.A., Inc. and as President of AstraZeneca’s U.S. Diabetes subsidiary. Most recently, Mr. Daly served as CEO, President, and Chairman of Neuralstem, Inc. Mr. Daly currently serves on the boards of Catalyst Pharmaceuticals and Opiant Pharmaceuticals.

Mr. Daly was instrumental in building Takeda North America from 14 people to more than 3,000 employees and $5 billion in sales in less than seven years. During his 13-year tenure, he served as Executive Vice President for the U.S., where he was responsible for business development for the Americas and expanding the company’s commercial footprint across North and South America and into new therapeutic areas, including oncology. As President of AstraZeneca’s U.S. Diabetes subsidiary, Mr. Daly led commercial initiatives that transformed the Bristol-Myers Squibb and AstraZeneca Diabetes Alliance into the fastest-growing diabetes franchise in the U.S. in less than 12 months.

Mr. Daly earned an M.B.A. from Northwestern University’s Kellogg School of Management and holds a B.S. in microbiology from the University of Notre Dame.

Close

Lan Huang, Ph.D.

Dr. Huang has served on the Board of Directors of Seed Therapeutics, Inc. since October 2020.

Dr. Huang brings over 15 years of entrepreneurial experience in the Chinese and U.S. biotechnology industries. In 2010, Dr. Huang founded Wanchun Biotech, the former holding company of BeyondSpring’s U.S. subsidiary. In 2007, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd., where she served as CEO in 2010 and continues to hold a directorship. The rights related to the development and marketing of the peptide drug in China, which drug Dr. Huang designed while at Wuxi MTLH Biotechnology Co. Ltd., were sold to Shanghai Pharmaceutical Co., Ltd. in 2010. Additionally, in 2008, Dr. Huang co-founded Paramax International Inc., a CRO that conducts clinical trials for global biopharmaceutical and medical device companies. Paramax International Inc. was acquired by ReSearch Pharmaceutical Services, Inc. in 2009. Dr. Huang was trained at Memorial Sloan Kettering Cancer Center from 1998 to 2002, where her research in cancer signaling pathways involving p53 degradation was published in Science. Her translational research in cancer signaling pathways involving RAS was published in two Nature papers. She has invented and holds patents for a number of biotech products for oncology and dermatology indications.

Dr. Huang received her B.A., Magna Cum Laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee from 2012 to 2015. She received her Ph.D. in chemistry from the University of California at Berkeley, where she won the international-level Women’s Opportunity Award given by Soroptimist International. She also studied at Fudan University in Shanghai, China.

Close

Edward Dongheng Liu

Mr. Liu has served on the Board of Directors of Seed Therapeutics, Inc. since October 2020.

Mr. Liu joins Seed Therapeutics with more than a decade of investment banking and investment experience in the Asia-Pacific region and currently is Chief Financial Officer, China for BeyondSpring, Inc.
Prior to joining BeyondSpring, Mr. Liu was a Partner and Executive Director at Epiphron Capital, a cross-border, healthcare-focused investment fund that was an early investor in BeyondSpring. Prior to that, he held various leadership positions in the investment banking industry based in Hong Kong focusing on clients in the Asia-Pacific region. He was Senior Vice President and Vice President at Investment Banking and Capital Markets at Jefferies. Prior to Jefferies, he served as Vice President at Investment Banking Division at J.P. Morgan. As an investment banker, Mr. Liu has led financing and M&A transactions for clients across sectors with a total transaction value exceeding US$30 billion.

Mr. Liu received his Bachelor’s degree in Economics and Mathematics from Yale University. He also completed biomedical engineering coursework at Tsinghua University.

BOARD OF DIRECTORS

Board of Directors
Lan Huang, Ph.D.

Lan Huang, Ph.D.

Co-founder, Chairman & Chief Executive Officer

Rich Daly
Richard Daly

Director

Close

Lan Huang, Ph.D.

Dr. Huang has served on the Board of Directors of Seed Therapeutics, Inc. since October 2020.

Dr. Huang brings over 15 years of entrepreneurial experience in the Chinese and U.S. biotechnology industries. In 2010, Dr. Huang founded Wanchun Biotech, the former holding company of BeyondSpring’s U.S. subsidiary. In 2007, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd., where she served as CEO in 2010 and continues to hold a directorship. The rights related to the development and marketing of the peptide drug in China, which drug Dr. Huang designed while at Wuxi MTLH Biotechnology Co. Ltd., were sold to Shanghai Pharmaceutical Co., Ltd. in 2010. Additionally, in 2008, Dr. Huang co-founded Paramax International Inc., a CRO that conducts clinical trials for global biopharmaceutical and medical device companies. Paramax International Inc. was acquired by ReSearch Pharmaceutical Services, Inc. in 2009. Dr. Huang was trained at Memorial Sloan Kettering Cancer Center from 1998 to 2002, where her research in cancer signaling pathways involving p53 degradation was published in Science. Her translational research in cancer signaling pathways involving RAS was published in two Nature papers. She has invented and holds patents for a number of biotech products for oncology and dermatology indications.

Dr. Huang received her B.A., Magna Cum Laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee from 2012 to 2015. She received her Ph.D. in chemistry from the University of California at Berkeley, where she won the international-level Women’s Opportunity Award given by Soroptimist International. She also studied at Fudan University in Shanghai, China.

Close

Richard Daly

Mr. Daly has served on the Board of Directors of Seed Therapeutics, Inc. since October 2020.

Mr. Daly joins the company with more than 25 years of experience leading business and commercial operations for major pharmaceutical and biotech companies, including Executive Vice President at Takeda Pharmaceuticals U.S.A., Inc. and as President of AstraZeneca’s U.S. Diabetes subsidiary. Most recently, Mr. Daly served as CEO, President, and Chairman of Neuralstem, Inc. Mr. Daly currently serves on the boards of Catalyst Pharmaceuticals and Opiant Pharmaceuticals.

Mr. Daly was instrumental in building Takeda North America from 14 people to more than 3,000 employees and $5 billion in sales in less than seven years. During his 13-year tenure, he served as Executive Vice President for the U.S., where he was responsible for business development for the Americas and expanding the company’s commercial footprint across North and South America and into new therapeutic areas, including oncology. As President of AstraZeneca’s U.S. Diabetes subsidiary, Mr. Daly led commercial initiatives that transformed the Bristol-Myers Squibb and AstraZeneca Diabetes Alliance into the fastest-growing diabetes franchise in the U.S. in less than 12 months.

Mr. Daly earned an M.B.A. from Northwestern University’s Kellogg School of Management and holds a B.S. in microbiology from the University of Notre Dame.

Edward Liu
Edward Dongheng Liu

Director

Close

Edward Dongheng Liu

Mr. Liu has served on the Board of Directors of Seed Therapeutics, Inc. since October 2020.

Mr. Liu joins Seed Therapeutics with more than a decade of investment banking and investment experience in the Asia-Pacific region and currently is Chief Financial Officer, China for BeyondSpring, Inc.
Prior to joining BeyondSpring, Mr. Liu was a Partner and Executive Director at Epiphron Capital, a cross-border, healthcare-focused investment fund that was an early investor in BeyondSpring. Prior to that, he held various leadership positions in the investment banking industry based in Hong Kong focusing on clients in the Asia-Pacific region. He was Senior Vice President and Vice President at Investment Banking and Capital Markets at Jefferies. Prior to Jefferies, he served as Vice President at Investment Banking Division at J.P. Morgan. As an investment banker, Mr. Liu has led financing and M&A transactions for clients across sectors with a total transaction value exceeding US$30 billion.

Mr. Liu received his Bachelor’s degree in Economics and Mathematics from Yale University. He also completed biomedical engineering coursework at Tsinghua University.

BOARD OF DIRECTORS

Board of Directors
Lan Huang, Ph.D.

Lan Huang, Ph.D.

Co-founder, Chairman & Chief Executive Officer

Close

Lan Huang, Ph.D.

Dr. Huang has served on the Board of Directors of Seed Therapeutics, Inc. since October 2020.

Dr. Huang brings over 15 years of entrepreneurial experience in the Chinese and U.S. biotechnology industries. In 2010, Dr. Huang founded Wanchun Biotech, the former holding company of BeyondSpring’s U.S. subsidiary. In 2007, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd., where she served as CEO in 2010 and continues to hold a directorship. The rights related to the development and marketing of the peptide drug in China, which drug Dr. Huang designed while at Wuxi MTLH Biotechnology Co. Ltd., were sold to Shanghai Pharmaceutical Co., Ltd. in 2010. Additionally, in 2008, Dr. Huang co-founded Paramax International Inc., a CRO that conducts clinical trials for global biopharmaceutical and medical device companies. Paramax International Inc. was acquired by ReSearch Pharmaceutical Services, Inc. in 2009. Dr. Huang was trained at Memorial Sloan Kettering Cancer Center from 1998 to 2002, where her research in cancer signaling pathways involving p53 degradation was published in Science. Her translational research in cancer signaling pathways involving RAS was published in two Nature papers. She has invented and holds patents for a number of biotech products for oncology and dermatology indications.

Dr. Huang received her B.A., Magna Cum Laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee from 2012 to 2015. She received her Ph.D. in chemistry from the University of California at Berkeley, where she won the international-level Women’s Opportunity Award given by Soroptimist International. She also studied at Fudan University in Shanghai, China.

Rich Daly
Richard Daly

Director

Close

Richard Daly

Mr. Daly has served on the Board of Directors of Seed Therapeutics, Inc. since October 2020.

Mr. Daly joins the company with more than 25 years of experience leading business and commercial operations for major pharmaceutical and biotech companies, including Executive Vice President at Takeda Pharmaceuticals U.S.A., Inc. and as President of AstraZeneca’s U.S. Diabetes subsidiary. Most recently, Mr. Daly served as CEO, President, and Chairman of Neuralstem, Inc. Mr. Daly currently serves on the boards of Catalyst Pharmaceuticals and Opiant Pharmaceuticals.

Mr. Daly was instrumental in building Takeda North America from 14 people to more than 3,000 employees and $5 billion in sales in less than seven years. During his 13-year tenure, he served as Executive Vice President for the U.S., where he was responsible for business development for the Americas and expanding the company’s commercial footprint across North and South America and into new therapeutic areas, including oncology. As President of AstraZeneca’s U.S. Diabetes subsidiary, Mr. Daly led commercial initiatives that transformed the Bristol-Myers Squibb and AstraZeneca Diabetes Alliance into the fastest-growing diabetes franchise in the U.S. in less than 12 months.

Mr. Daly earned an M.B.A. from Northwestern University’s Kellogg School of Management and holds a B.S. in microbiology from the University of Notre Dame.

Edward Liu
Edward Dongheng Liu

Director

Close

Edward Dongheng Liu

Mr. Liu has served on the Board of Directors of Seed Therapeutics, Inc. since October 2020.

Mr. Liu joins Seed Therapeutics with more than a decade of investment banking and investment experience in the Asia-Pacific region and currently is Chief Financial Officer, China for BeyondSpring, Inc.
Prior to joining BeyondSpring, Mr. Liu was a Partner and Executive Director at Epiphron Capital, a cross-border, healthcare-focused investment fund that was an early investor in BeyondSpring. Prior to that, he held various leadership positions in the investment banking industry based in Hong Kong focusing on clients in the Asia-Pacific region. He was Senior Vice President and Vice President at Investment Banking and Capital Markets at Jefferies. Prior to Jefferies, he served as Vice President at Investment Banking Division at J.P. Morgan. As an investment banker, Mr. Liu has led financing and M&A transactions for clients across sectors with a total transaction value exceeding US$30 billion.

Mr. Liu received his Bachelor’s degree in Economics and Mathematics from Yale University. He also completed biomedical engineering coursework at Tsinghua University.

CAREERS

careers

Head – Drug Discovery Chemistry

The successful Head of Drug Discovery Chemistry will design, implement, and run the Seed Therapeutics drug discovery chemistry department.
Apply Now

Head – Drug Discovery Research

The successful Head of Drug Discovery Research will design, implement, and run the Seed Therapeutics drug discovery research department.
Apply Now

Please contact James Tonra at james.tonra@seedtherapeutics.com for these positions to find out more.

CONTACT US

contact us

Seed Therapeutics, Inc.
28 Liberty Street, 39th Floor New York, NY 10005, United States